^
    Back
    Association details:
    Biomarker:EGFR expression
    Cancer:Non Small Cell Lung Cancer
    Drug:Tyvyt (sintilimab) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO Asia 2020
    Title:

    402P - Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) (ID 567)

    Published date:
    11/17/2020
    Excerpt:
    Eligible pts would receive docetaxel (75mg/m2, day 1) plus sintilimab (200mg, day 3)...Estimated median PFS was 5.5m (95%CI 3.6-NE)...Of the 25 evaluable pts, ORR is 24% (95%CI 9%, 45%), DCR is 92% (95%CI 74%, 99%)...EGFR/ALK positive pts….advanced Chinese NSCLC pts...
    Secondary therapy:
    docetaxel